Related references
Note: Only part of the references are listed.Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
J. A. Woyach et al.
LEUKEMIA (2012)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Matthias Niedermeier et al.
BLOOD (2009)
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A. Phelps et al.
BLOOD (2009)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Syed-Rehan A. Hussain et al.
BLOOD (2008)
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
Michael R. Grever et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Share Paper
